<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18645517</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>09</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1525-4135</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>48</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2008</Year>
<Month>Aug</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of acquired immune deficiency syndromes (1999)</Title>
<ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation>
</Journal>
<ArticleTitle>Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.</ArticleTitle>
<Pagination>
<MedlinePgn>561-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0b013e31817bebeb</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Corticosteroids are cytochrome P450 3A4 substrates, which have been associated with toxicities in patients receiving cytochrome P450 3A4 inhibitors such as human immunodeficiency virus protease inhibitors. In a study in healthy volunteers, ritonavir significantly increased prednisolone exposure.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We investigated the influence of antiretroviral (ARV) medications on prednisolone pharmacokinetics in 3 groups of 10 human immunodeficiency virus-infected subjects. One group received lopinavir/ritonavir, and another efavirenz, as part of their ARV regimen; a third group did not receive ARV medications. Each subject received a single 20-mg prednisone dose followed by serial blood sampling for prednisolone. Prednisolone pharmacokinetics were compared among the groups.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Area under the concentration-time curve was significantly lower in efavirenz recipients versus subjects receiving lopinavir/ritonavir (geometric mean ratio = 0.60, P = 0.01). Average prednisolone area under the concentration-time curve was higher in subjects taking lopinavir/ritonavir versus subjects not on ARVs; however, this difference was not significant (P &gt; 0.05).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that prednisolone concentrations may fluctuate widely when human immunodeficiency virus-positive individuals established on efavirenz therapy change to lopinavir/ritonavir or vice versa.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Busse</LastName>
<ForeName>Kristin H</ForeName>
<Initials>KH</Initials>
<AffiliationInfo>
<Affiliation>Pharmacy Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Formentini</LastName>
<ForeName>Elizabeth</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alfaro</LastName>
<ForeName>Raul M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kovacs</LastName>
<ForeName>Joseph A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Penzak</LastName>
<ForeName>Scott R</ForeName>
<Initials>SR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>Z01 CL005096-05</GrantID>
<Acronym>NULL</Acronym>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Acquir Immune Defic Syndr</MedlineTA>
<NlmUniqueID>100892005</NlmUniqueID>
<ISSNLinking>1525-4135</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
<NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>JE6H2O27P8</RegistryNumber>
<NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CitationSubset>X</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019380">Anti-HIV Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D048588">Benzoxazines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017320">HIV Protease Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D061466">Lopinavir</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011239">Prednisolone</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011744">Pyrimidinones</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018894">Reverse Transcriptase Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019438">Ritonavir</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>7</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18645517</ArticleId>
<ArticleId IdType="doi">10.1097/QAI.0b013e31817bebeb</ArticleId>
<ArticleId IdType="pmc">PMC2669927</ArticleId>
<ArticleId IdType="mid">NIHMS101343</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Lancet. 1997 May 3;349(9061):1294</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9142067</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Sex Transm Infect. 1999 Aug;75(4):274</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10615321</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS. 2007 Feb 19;21(4):529-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17301576</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):307-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15980690</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Bone Joint Surg Br. 1977 Aug;59(3):308-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">893509</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hopkins HIV Rep. 1999 Jul;11(4):9-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11366924</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Pharmacokinet. 1990 Aug;19(2):126-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2199128</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):573-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16284534</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):303-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10901135</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2002 Sep 15;35(6):E69-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12203188</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS. 1999 Sep 10;13(13):1803</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10509596</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1987 Apr 18;1(8538):902-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2882300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Transplant. 1999 May;3(2):126-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10389134</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1998 Mar 26;338(13):853-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9516219</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Infect Dis J. 2006 Nov;25(11):1044-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17072128</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Clin Pharmacol. 2007 May;63(5):479-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17345073</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pediatr. 2006 Mar;148(3):386-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16615973</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS. 2003 Jan 3;17(1):1-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12478064</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Psychopharmacol. 2003 Dec;23(6):652-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14624194</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect. 2002 Apr;44(3):194-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12099750</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Intern Med. 2002 Jul 2;137(1):17-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12093241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>HIV Med. 2003 Apr;4(2):149-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12702137</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Metab Dispos. 1995 Jan;23(1):137-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7720517</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS Patient Care STDS. 2007 Jun;21(6):373-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17594245</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Endocrinol Metab. 2005 Jul;90(7):4394-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15755851</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Pharmacother. 2007 Jul;41(7):1306-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17535841</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Pharmacol Ther. 1989 Apr;45(4):366-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2639662</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):19-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11064500</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Intern Med J. 2005 Jan;35(1):67-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15667475</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>AIDS. 2005 Apr 29;19(7):740-1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15821405</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):281-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12626887</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Steroid Biochem Mol Biol. 1997 Jul;62(4):345-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9408089</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2001 Aug 15;184(4):519-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11471113</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Clin Pharmacol. 2000 Apr;56(1):57-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10853878</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>